Disease relevance of ioversol

• In contrast, ioversol and iohexol induced significant pulmonary edema only after the injection of large doses (6 g of iodine per kilogram; P < .05) [1].
• In Segments I, II, and III reproductive toxicity studies, ioversol did not produce teratogenic effects in either rats or rabbits at daily intravenous dose levels of up to 3.2 g I/kg/day [2].
• The spontaneous ventricular fibrillation (VF) potential of the nonionic contrast media, ioversol (IOV), with and without the addition of sodium was examined during right coronary artery (RCA) injections into anesthetized closed-chest dogs [3].
• Hypersensitivity reaction to ioversol [4].
• In peripheral arteriography, there was less discomfort with ioversol as well as decreased magnitude and incidence of hypotension (P less than .001) after injection [5].

High impact information on ioversol

• Because of the significant first-pass myocardial retention of ioversol, both mean myocardial appearance time and intramyocardial blood volume were consistently overestimated [6].
• We tested this assumption by comparing a conventional nonionic contrast agent (ioversol) to a particulate emulsion (ethiodol) that remained in the vascular space in closed-chest dogs during pharmacological vasodilation [6].
• In mice with unilateral renal occlusion, ioversol increased urinary excretion of N-acetyl-beta-d-glucosaminidase with concomitant decreases in Bcl-2 mRNA, increases in Bax mRNA, activation of caspase-3, and induction of apoptosis in tubular and interstitial cells [7].
• Ioversol, a radiocontrast medium, caused cell injury accompanied by decreases in Bcl-2, increases in Bax, and caspase activation in LLC-PK1 cells [7].
• Hexabrix and Optiray induced histamine and tryptase release from human lung mast cells, but not from human skin mast cells [8].

Chemical compound and disease context of ioversol

• To determine whether sodium attenuates or potentiates ventricular fibrillation from nonionic contrast media, we measured the prolongation in QT interval and performed programmed electrical stimulation with one, two and three extra ventricular stimuli in 40 dogs during 4-mL intracoronary injections of iopamidol, iohexol, and ioversol [9].
• Iopromide and ioversol induced transient changes in blood pressure (decrease followed by an increase), left ventricular end-diastolic pressure (increase), heart rate (decrease), contractility (increase followed by decrease), and electrocardiogram (extrasystoles, ST depression) [10].

Biological context of ioversol

• RESULTS: Beraprost sodium (10 to 1000 nmol/L) attenuated concentration dependently the ioversol-induced decrease in cell viability, in which the protective effect of beraprost sodium was dependent on the elevation of cellular cAMP content [11].
• METHODS: Isolated mouse proximal tubule segments (PTS), or cultured proximal tubule (HK-2) cells, were subjected to radiocontrast media (RCM) (Ioversol, Optiray 320) exposure, followed by assessments of cellular viability [% lactate dehydrogenase (LDH) release, tetrazolium dye (MTT), uptake] and lipid peroxidation [12].
• Safety and pharmacokinetics of ioversol in healthy volunteers [13].
• Reproductive, developmental, and genetic toxicology of ioversol [2].
• The median lethal dose (LD50) of ioversol administered intravenously to mice, rats, rabbits, and dogs was more than 12 g I/kg, which exceeds the maximal anticipated clinical dose by at least tenfold [14].

Anatomical context of ioversol

• Induction of micronuclei in lymphocytes of patients undergoing excretory urography with ioversol [15].
• Recovery of ioversol in urine and feces averaged 86% to 88% of the administered dose, of which all but a few percent was recovered in urine [16].
• METHODS: Preoperatively, we marked the visceral pleura near the pulmonary nodules with dye, simultaneously injected contrast media (1 water-soluble Optiray [Mallinckrodt Medical Inc, Quebec, Canada], 18 barium sulfate, 11 Lipiodol [Laboratoire Guerbet, Aulnay-sous-Bois, France]) into or around the nodule under computed tomography (CT) guidance [17].
• RATIONALE AND OBJECTIVES: Enhancement characteristics of a nonionic, dimeric, isotonic contrast medium (iodixanol [Visipaque]) were compared with a nonionic, monomeric contrast medium (ioversol [Optiray]) of the same iodine concentration in spiral computed tomography angiography (CTA) of the abdominal aorta [18].
• In comparison with iothalamate, ioversol had a greatly reduced propensity to stimulate the release of endothelin, from cultured cells and when injected into anesthetized rats [19].

Associations of ioversol with other chemical compounds

• The four newly introduced contrast agents--iopamidol, iohexol, ioversol, and ioxaglate--are of much lower osmolality than conventional agents, and claims have been made that they are substantially safer [20].
• RESULTS: In vitro, the attenuation of undiluted gadodiamide (3,069 HU) was equivalent to that of ioversol diluted to 106 mg of iodine per milliliter and at equimolar concentrations was 50% greater than that of ioversol [21].
• Overall, the incidence of ECG changes was small in both groups (ioversol 2%, diatrizoate 8%) [5].
• Following left ventriculography, diatrizoate caused a greater increase in cardiac output, left ventricular end diastolic pressure, and corrected QT interval while causing a greater decrease in arterial pressure than did either ioversol or iopamidol, which were indistinguishable from each other [22].
• In a controlled double-blind study, ioversol 320 versus iopamidol-300 was tested on 60 patients in cerebral angiography [23].

Gene context of ioversol

• FB(1) reversed ioversol-induced decrease in the immunoreactivities of pAkt and pCREB, reduction in Bcl-2 expression and caspase-3 activation [24].
• Diatrizoate, ioxaglate, and ioversol inhibited plasminogen binding to plasma clots by 51+/-4% (p<0.001), 30.1+/-4% (p<0.01), and 19.4+/-7% (p=0.07), respectively [25].
• Ioversol enhanced the activities of caspase-3 and -9, but to a lesser extent, caspase-8 [26].
• The cell damage induced by a non-ionic contrast medium ioversol was inhibited by specific inhibitors for caspase-3 and -9 but not caspase-8 [26].
• The effects of the nonionic, low osmolar agent, ioversol, on endothelin release and renal function are investigated [19].

Analytical, diagnostic and therapeutic context of ioversol

• MATERIALS AND METHODS: Arterial phase helical CT (3-mm collimation, 1-mm reconstruction interval) was performed during power injection of 180 mL of ioversol at 5 mL/sec [27].
• A randomized, double-blind study of a new nonionic contrast agent (ioversol) was performed in 80 patients undergoing routine coronary angiography and left ventriculography [28].
• The author concludes that ioversol is suitable for head and body computed tomography, intravenous urography, and venography [29].
• A total of 3854 adult patients were studied (1931 ioversol, 1923 reference) from 57 clinical trials [30].
• We conclude that ioversol is safe and efficacious for peripheral and visceral arteriography [5].

References